# Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects

> **NCT07697560** · PHASE1 · RECRUITING · sponsor: **AnHorn Medicines Co. Ltd.** · enrollment: 32 (estimated)

## Conditions studied

- Chemotherapy-induced Peripheral Neuropathy (CIPN)

## Interventions

- **DRUG:** AH-008 for Injection, 150 mg
- **DRUG:** AH-008 for Injection, Placebo

## Key facts

- **NCT ID:** NCT07697560
- **Lead sponsor:** AnHorn Medicines Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-10
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07697560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07697560, "Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07697560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*